杀害班花逃15年

医保基金即时结算改革目标均突破90%_我的网站

一 |     

    Photo： VCG
China reported 522,000 newly confirmed COVID-19 cases in July, including 487 severe cases and one related death with cases showing a fluctuating upward trend, China's national disease control authority said. 
The current uptick in infections represents another regular cyclical wave, with its severity comparable to surges seen in the past two years. The upward growth curve has slowed markedly, and the country is now on the plateau phase of this epidemic peak, said the Chinese Center for Disease Control and Prevention (Chinese CDC) on Thursday. 
All tested infection samples were confirmed to be the Omicron variant, with the NB.1.8.1 strain and its sublineages accounting for the majority of circulating cases, the Chinese CDC said. 
A Beijing-based respiratory disease specialist told the Global Times that waning population immunity, continued virus mutations that weaken existing antibody protection, and increased summer travel have contributed to the recent modest rise in infections. However, there is no evidence that the virus has become more pathogenic. Nationwide infections appear to be nearing their peak and case numbers may begin falling in late August. 
    A screenshot from Chinese CDC report on new COVID-19 cases in July nationwide
According to sentinel hospital surveillance data, from June 29-July 5 to July 27-August 2, the proportion of influenza-like illness among all outpatient and emergency visits at China's 1,041 COVID-19 and influenza sentinel hospitals edged up with slight fluctuations, standing at 4.3 percent, 4.4 percent, 4.5 percent, 4.4 percent and 4.5 percent, respectively.
During the same period, the COVID-19 positivity rate among patients with influenza-like illness in outpatient and emergency departments rose for consecutive weeks.
Several factors drove the fluctuating rise in COVID-19 cases in July. Population immunity has waned, as more than six months have passed since the last major wave of infections for most people, while continued SARS-CoV-2 mutations have reduced the protection provided by existing antibodies, Li Tongzeng, a respiratory disease medic from Beijing You An Hospital to the Capital Medical University, told the Global Times on Friday. 
These factors, combined with increased travel and population mobility during the summer vacation, contributed to the recent small-scale surge. Based on patterns observed in recent years, COVID-19 infections tend to rise every six to eight months as population immunity declines, said Li.
The expert noted that while the virus continues to mutate, there is no evidence that it has become more pathogenic. Clinical data show that most patients develop only mild symptoms, with very few progressing to pneumonia or requiring hospitalization.
The Chinese CDC noted on Thursday that since COVID-19 was reclassified as a Category B infectious disease under Category B management, it has evolved into a prevalent, recurring respiratory infectious disease in China, with one to two epidemic fluctuations occurring nationwide each year.
Li also noted that residual immunity from previous infections also helps reduce disease severity, with most reinfections presenting as mild upper respiratory symptoms that resolve within about a week. The single COVID-related death reported nationwide in July further indicates that the current fatality rate remains very low.
Judging from historical epidemic patterns and current case growth trajectories, national infection figures may begin to decline in late August. Nationwide case numbers are now nearly at their peak, with declines already observed in some regions, said Li. 
The Chinese CDC also said on Thursday that surveillance had not detected any variants posing major public health risks, nor had the current wave caused notable disruptions to the healthcare system.
The public is advised to take appropriate protective measures, including wearing masks when necessary, maintaining good personal hygiene, adopting healthy lifestyles and getting vaccinated as recommended.
。    　　讯 据国家医保局消息，根据初步统计，截至2026年7月底，全国医保部门共拨付医药机构即时结算资金9457.31亿元，占本地月结算资金规模的95.51%；覆盖定点医药机构75.22万家，占统筹地区定点医药机构数量的90.17%。即时结算年度目标任务提前完成，改革速度超预期、改革成效已彰显。　　据悉，2025年10月，国家医保局印发《关于全面推进医保基金即时结算改革扩面提质的通知》（医保办函〔2025〕82号），要求2026年底前实现即时结算资金占本地医保基金月结算资金的80%以上，开通即时结算定点医疗机构占比达到80%以上。地方医保部门加快推进医保基金即时结算改革，通过压缩结算周期、提高拨付频次、按月预拨等方式，最大限度压缩与定点医药机构的结算周期，切实帮助定点医药机构缓解资金流压力，有力助推公立医疗机构取消门诊预交金、降低住院预交金额度，减轻了参保群众就医的经济负担。　　随着医保基金即时结算改革的全面实施，标志着医保基金结算从“被动支付”向“主动赋能”转变，必将为深化医药卫生体制改革、促进“三医”协同发展注入强劲动力，不断增强人民群众医疗保障获得感、幸福感和安全感。版权申明：凡注有“”或电头为“”的稿件，均为独家版权所有，未经许可不得转载或镜像；授权转载必须注明来源为“”，并保留“”的电头。    。

Current article:http://jyt7cvq.dinggaxilianmaiyuejienianguai.shop/news/20260826_5335806.html

Published on:11:45:21